Asset Details
Do you wish to reserve the book?
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
Do you wish to request the book?
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
2013
Overview
In vitro studies suggest that haploinsufficiency is involved in the pathogenesis of myelodysplastic syndromes (MDS). In patients with del5q cytogenetic abnormality, RPS-14 and microRNAs (miRNAs) play a major role. In a multicenter phase II single-arm trial with lenalidomide in anemic primary del5q MDS patients with low- or int-1 risk IPSS, biological changes from baseline were investigated. Gene expression profiling of selected genes was performed (TaqMan® Low Density Array Fluidic card, Applied Biosystems PRISM® 7900HT) and normalized against the expression of the 18S housekeeping gene from a pool of healthy subjects. Thirty-two patients were evaluated at baseline and after 3 and 6 months of treatment. RPS-14, miR-145, and miR-146 were downregulated at baseline and significantly increased during treatment. Nuclear factor kappa B, IL-6, interferon regulatory factor-1, IFNγ-R2, IL-2, and many genes in the apoptotic pathways (TNF, IL-1B, and IL-10) were upregulated at baseline and significantly downregulated during lenalidomide treatment, while forkhead box P3, FAS, IFNγ, IL-12A, and IL-12B were downregulated at baseline and progressively upregulated during treatment. The crucial role of aberrant immunological pathways and haploinsufficiency in the pathogenesis of del5q MDS is confirmed in the present patient setting. Our results indicate that lenalidomide may act through defined immunological pathways in this condition.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
/ Anemia, Macrocytic - drug therapy
/ Anemia, Macrocytic - genetics
/ Anemia, Macrocytic - immunology
/ Bone Marrow Cells - metabolism
/ Bone Marrow Cells - pathology
/ Chromosomes, Human, Pair 5 - genetics
/ Chromosomes, Human, Pair 5 - immunology
/ Female
/ Forkhead Transcription Factors - biosynthesis
/ Forkhead Transcription Factors - genetics
/ Gene Expression Regulation - drug effects
/ Humans
/ Male
/ Medicine
/ Myelodysplastic Syndromes - drug therapy
/ Myelodysplastic Syndromes - genetics
/ Myelodysplastic Syndromes - immunology
/ Oncology
/ Ribosomal Proteins - deficiency
/ Ribosomal Proteins - genetics
/ Signal Transduction - genetics
/ Signal Transduction - immunology
